Skip to main content

BioVersys extends Series C financing round to 44.9 million Swiss francs

| News

BioVersys extends Series C financing round to 44.9 million Swiss francs


Basel-based BioVersys is bolstering its partnership with GSK in order to accelerate the development of alpibectir for the treatment of tuberculosis. GSK is set to participate in BioVersys’s Series C financing round, which is being extended by 12.3 million to 44.9 million Swiss francs in total.

The Basel-based biopharmaceutical company BioVersys has announced an expanded strategic partnership with GSK and the extension of its Series C financing round by 12.3 million Swiss francs. According to a press release, the clinical development of alpibectir for the treatment of tuberculosis (TB) is to be accelerated in conjunction with GSK.

Developed in collaboration between GSK, the Pasteur Institute of Lille and the University of Lille, alpibectir is currently being studied in pulmonary TB patients in South Africa. The active ingredient represents a completely new concept for overcoming resistance, as the press release states. GSK and BioVersys will continue to work together beyond the current Phase 2a study to make alpibectir available to patients as quickly as possible.

As part of the expanded collaboration, GSK will participate in the latest BioVersys financing round with an equity investment, according to the press release. Together with further investments from existing and new investors, the Series C financing round will be extended by 12.3 million Swiss francs, bringing the total proceeds from the previous Series C financing round to 44.9 million Swiss francs overall.

New treatment plan for tuberculosis

“Together with GSK, we successfully advanced the development of alpibectir for TB, having recently completed the TRIC-TB public-private partnership program with the delivery of a Phase 2-ready anti-TB molecule”, as Dr. Marc Gitzinger, Chief Executive Officer and founder of BioVersys, explains in the press release. The aim of the collaboration with GSK is to develop a new treatment plan for tuberculosis, Gitzinger states.

“GSK is committed to changing the trajectory of tuberculosis and we’re excited to expand our partnership with BioVersys in the continued development of alpibectir, a drug candidate with the potential to broaden the treatment options for TB”, comments Thomas Breuer, Chief Global Health Officer at GSK, in the press release.

You may also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.